Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2017

CLL

View all
3:20
CLL updates from ASH 2017
Jacqueline Barrientos • 9 Dec 2017
2:04
MURANO trial: revolutionizing the standard of care for relapsed CLL patients
Stephan Stilgenbauer • 11 Dec 2017

MM

View all
4:48
Curative strategy for smoldering multiple myeloma: GEM-CESAR
Maria-Victoria Mateos • 9 Dec 2017
2:45
MRD-guided high-dose carfilzomib treatment for multiple myeloma
Ola Landgren • 9 Dec 2017

AML

View all
2:25
Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs
Marina Konopleva • 9 Dec 2017
3:08
AML highlights from ASH 2017
Charles Craddock • 9 Dec 2017

Lymphoma

View all
0:46
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
Nirali Shah • 9 Dec 2017
1:44
Treating lymphoma beyond progression
Graham Collins • 9 Dec 2017

ALL

View all
2:13
Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVD
Susan O’Brien • 9 Dec 2017
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals